Elan Corporation PLC - Re Co-promotion of Drug

RNS No 3617k
ELAN CORPORATION PLC
14th July 1997



             ELAN AND WYETH-AYERST TO EXPAND NAPRELAN PROMOTION              
                                                                              
          - Athena to co-promote Naprelan through new sales force -           

DUBLIN, IRELAND/PHILADELPHIA, PENNSYLVANIA, July 14, 1997 - - Athena
Neurosciences, Inc (Athena), a wholly-owned subsidiary of Elan Corporation,
plc (Elan) (NYSE: ELN) and Wyeth-Ayerst Pharmaceuticals (Wyeth-Ayerst), a
division of American Home Products Corporation (NYSE: AHP) announced today
that they had reached an agreement for expanded promotion of Naprelan
(naproxen sodium) controlled-release tablets to neurologists and physical
medicine and rehabilitation specialists throughout the United States by
Athenas new Elan Pharma sales force.

Naprelan, originally developed by Elan and licensed to American Home Products
Corporation, features Elans proprietary IPDAS (Intestinal Protective Drug
Absorption System) technology.  Naprelan is the only once-a-day formulation of
naproxen sodium, a non-steroidal anti-inflammatory (NSAID).  Introduced in
1996 by Wyeth-Ayerst, Naprelan is indicated for the treatment of
osteoarthritis, rheumatoid arthritis and mild-to-moderate pain.

Michael D. Coffee, Athenas president and chief operating officer, noted that
the co-promotion of Naprelan by our Elan Pharma sales force marks the true
realization of Elans Mind-to-Market strategy and will provide this sales group
the opportunity to begin calling on physicians immediately.

Robert Essner, president of Wyeth-Ayerst Pharmaceuticals, commented, this
agreement expands our broad partnership with Elan and Athena into the
physicians office.  We expect that Athenas efforts will further complement our
support of Naprelan and expand on its successful introduction last year.

Elan is a leading worldwide drug delivery and biopharmaceutical company with
its principal research and manufacturing facilities in Ireland, the United
States and Israel. Elans shares trade on the New York, London and Dublin Stock
Exchanges.

Wyeth-Ayerst Pharmaceuticals is a major research-oriented pharmaceutical
company with leading products in the areas of womens health care,
cardiovascular and metabolic disease therapies, central nervous system drugs,
anti-inflammatory agents, vaccines and generic pharmaceuticals.

American Home Products is one of the worlds largest research-based
pharmaceutical and health care product companies.  It is a leader in the
discovery, development, manufacturing and marketing of prescription drugs and
over-the-counter medications.  It is also a global leader in vaccines,
biotechnology, agricultural products, animal health care and medical devices.

The statements in this press release may include forward-looking statements
that involve risks and uncertainties, including, without limitation, risks
associated with the inherent uncertainty of commercialization of Naprelan, the
impact of competitive products and third party reimbursement risks associated
with the pharmaceutical industry, and the other risks and uncertainties
detailed from time to time in periodic reports, including the American Home
Products Corporation, its quarterly reports on Form 10-Q and the annual report
on Form 10-K, and, for Elan Corporation, plc, its annual report on Form 20-F,
filed with the Securities and Exchange Commission.  Actual results may differ
from the forward-looking statements.

For further information contact:

Mary Bingham
Director, Investor Relations, Elan 
Ph: 212-755-3218

Eric J. Liebler
Director, External Relations, Athena 
Ph: 415-877-7662

Douglas Petkus
Wyeth-Ayerst
Ph: 610-971-4980



END

Rolls-r 24 (LSE:43AI)
과거 데이터 주식 차트
부터 12월(12) 2024 으로 1월(1) 2025